论文部分内容阅读
探索多线治疗失败的人表皮生长因子受体2(human epidermal growth factor receptor 2，Her-2)阳性乳腺癌患者的治疗方案。我们对收治的1例难治性Her-2阳性乳腺癌患者的临床资料进行回顾性分析。该患者初诊即为Her-2阳性晚期乳腺癌，经过外院六线治疗病情基本上处于进展状态，乳腺肿瘤破溃流脓，双肺转移灶增大增多，患者生存质量较差。该患者入住徐州医科大学附属宿迁医院后，经过MDT讨论后，我们给予吡咯替尼联合卡培他滨方案治疗，患者胸部创面逐渐愈合，肺内转移灶逐渐减少、缩小，生活质量较好。对该病例的回顾性分析结果表明对于多线治疗失败的Her-2阳性乳腺癌患者，特别是靶向治疗失败的患者，应用吡咯替尼联合卡培他滨方案或许能给此类患者带来希望。“,”In order to explore the treatment of Her-2 positive breast cancer patients who failed in multi-line treatments, we retrospectively analyzed the clinical data of a patient with refractory Her-2 positive breast cancer.The patient was initially diagnosed as Her-2 positive advanced breast cancer.After six line treatment in the outer hospital, the patient′s condition was basically in a progressive state.The breast tumor was broken and purulent, the lung metastasis increased, and the patient′s quality of life was poor.The patient was admitted to Department of Breast Surgery of Affiliated Suqian Hospital of Xuzhou Medical University, after MDT discussion, we gave pyrrolotinib combined with capecitabine treatment, the chest wound healed gradually, the lung metastasis gradually reduced, and the quality of life was better.A retrospective analysis of this case showed that pyrrolidine combined with capecitabine may bring hope to Her-2 positive breast cancer patients who failed to receive multi-line therapies, especially those who failed to target therapy.